Definitive Contract HHSN261201600038C

This is a $1,484,350.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc., a small business Subchapter S Corporation. The contract is for cell-based models for prostate cancer health disparity research as part of the Cancer Moonshot program (Phase II). The contract has a total small business set aside designation and an ultimate completion date of November 16, 2021. This award builds upon a previous contract with...

<p>The U.S. National Cancer Institute awarded a $299,502 Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a small business located in Gaithersburg, Maryland. The contract is for the development of &quot;Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation Late Effects.&quot; This is a Firm Fixed Price definitive contract with a period of performance through September 18, 2017.</p>

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>

<p>This is a $1,903,095.00 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc. on September 9, 2019. The contract is for TOPIC 345: PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS, with a period of performance through March 15, 2022. The contract does not have a set-aside designation.</p>

This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...

The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...

This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled &quot;Non-Invasive Subtyping of Aggressive Tumor and Its Environment&quot; as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...

This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Zymeron Corporation, a Minority Owned Small Business. The $349,790 Firm Fixed Price contract supports research and development of &quot;Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention.&quot; This work is part of the NIH/CDC SBIR Program, which aims to stimulate technological...

<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>